Based in France, BliNK Biomedical is a startup.
BliNK Biomedical develops B cell–based antibody discovery technology to identify and isolate very rare antibody-secreting cells from humans and other species. Their validated platforms (ISAAC and VIVA|Screen) are used to discover and isolate therapeutic antibodies for difficult targets.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.